Oragenics Files 8-K on Shareholder Nominations
Ticker: OGEN · Form: 8-K · Filed: May 23, 2024 · CIK: 1174940
Sentiment: neutral
Topics: governance, shareholder-action
TL;DR
Oragenics filed an 8-K regarding shareholder nominations - board changes might be coming.
AI Summary
On May 23, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns shareholder nominations pursuant to Exchange Act Rule 14a-11, indicating potential changes or proposals related to the company's board of directors or governance structure. No specific financial transactions or material events beyond this procedural filing were detailed in the provided excerpt.
Why It Matters
This filing signals potential changes in Oragenics' board composition or strategic direction, which could impact future company performance and shareholder value.
Risk Assessment
Risk Level: medium — Filings related to shareholder nominations and potential board changes can indicate internal disputes or strategic shifts, introducing uncertainty.
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- May 23, 2024 (date) — Date of Report
- Exchange Act Rule 14a-11 (legal_document) — Subject of filing
FAQ
What is the primary purpose of this 8-K filing for Oragenics, Inc.?
The primary purpose of this 8-K filing is to report shareholder nominations pursuant to Exchange Act Rule 14a-11.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is May 23, 2024.
What is Oragenics, Inc.'s state of incorporation?
Oragenics, Inc. is incorporated in Florida (FL).
What is the principal executive office address for Oragenics, Inc.?
The principal executive office address is 1990 Main Street, Suite 750, Sarasota, FL 34236.
What is the SIC code for Oragenics, Inc.?
The Standard Industrial Classification (SIC) code for Oragenics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 618 words · 2 min read · ~2 pages · Grade level 14.3 · Accepted 2024-05-23 09:27:30
Filing Documents
- form8-k.htm (8-K) — 39KB
- 0001493152-24-021103.txt ( ) — 208KB
- ogen-20240523.xsd (EX-101.SCH) — 3KB
- ogen-20240523_lab.xml (EX-101.LAB) — 33KB
- ogen-20240523_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 23 rd day of May, 2024. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Financial Officer